but clinically significant under-grading in biopsy GS=7. Over-grading is limited and present in 12 to 16% of biopsy GS 7-10. Only 21.5% of all patients with locally ad- vanced PCa have no GS 7-10 PCa at histo- pathology compared to 43% on biopsy. This has important implications for the management of locally advanced disease, as this warrants an aggressive treatment approach for all patients, including those with GS6 at biopsy. UP-2.121 Assessment of Atorvastatin Effectiveness on Serum PSA Level in Hypercholestrolemic Males Khosropanah I, Falahatkar S, Panahandeh Z, Farhat B GUMS, Urology Reseach Center, Rasht, Iran Introduction and Objective: The goal of this study is to survey Atorvastatin effec- tiveness in short term on serum PSA level (primary marker for prostate cancer risk) in hypercholestrolemic male patients. Materials and Methods: That is a non- randomized controlled prospective clinical trial, among the newly diagnosed males with hypercholesterolemia (LDL 130 mg/dl), 40 patients with LDL more than 190 mg/dl were selected as a case group and treated with Atorvastatin (20 mg/day). Among the same population and in the same period, another 40 patients with LDL between 130 to 190 mg/dl were se- lected as first control group and treated with low fat diet. Another 40 patients with normal serum cholesterol and with- out any treatment, were selected as sec- ond control group. The lipid profile (T.G, Total cholesterol, LDL, HDL) and serum PSA level of patients of all groups were tested at first and 3 months later. The common inclusion criteria in all groups were males with the age range of 40 to 70 years, absece of any prostatic disease (BPH, prostate cancer and clinically pros- tatitis) and serum PSA level lower than 4 ng/ml for males between 50 and 70 years, and lower than 2.5 ng/ml for males be- tween 40 and 50 years. Common exclu- sion criteria in all groups were docu- mented recent UTI and history of receiving statins or any drug for more than a week. After completion of data, the mean of serum lipids and PSA level were calculated in both tests and compared with eachother by paired t-test. Also the mean PSA change in two tests between these three groups were compared by Anova and Tukey HSD test. Results: Mean baseline PSA in hypercho- lestrolemic and normocholestrolemic pa- tients was 1.440.55 and 1.370.64, re- spectively that was not significantly different between them (P=0.547). In case group, mean PSA was reduced by 14.1% that was statistically significant (P=0.0001). Also, mean LDL reduced by 30% that was statistically significant (P=0.0001). In first control group mean PSA was reduced by 1.4% that was not statistically significant (P=0.337) whereas mean LDL was reduced by 9.6% that was statistically significant (P=0.0001). In sec- ond control group, mean PSA was in- creased by 0.7% that was not statistically significant (P=0.309). In addition mean change of PSA in case group was com- pared with first and second control groups that was significantly different (P=0.0001) whereas mean change of PSA between two control groups was not sig- nificantly different (P=0.615). Conclusions: The results of this study showed that first, short-term treatment with Atorvastatin cause reduction in se- rum PSA level, and second, this reduction is more likely due to direct drug effect and is not related to lowering serum cho- lesterol. The effect of drug on serum PSA level is likely due to antiproliferative and apoptotic effects of statins on latent pros- tate cancer cell lines demonstrated in in vitro and in vivo animal studies. There- fore, if results of this study are demon- strated by larger prospective randomized clinical trials with longer follow up pe- riod, it is possible that we use atorvastatin in the long-term period as a safe chemo- prophylactic agent in high risk patients. UP-2.122 Impact of Docetaxel on Dexamethasone Therapy in Hormone Refractory Prostate Cancer Kume H, Akiyama Y, Suzuki M, Fujimura T, Fukuhara H, Enomoto Y, Nishimatsu H, Takeuchi T, Homma Y The University of Tokyo Hospital, Tokyo, Japan Introduction: Docetaxel (TAX) based chemotherapy has been effective and well tolerated by Western patients with meta- static hormone refractory prostate cancer (HRPC). TAX was approved in Japan in August, 2008. At the present time it is in a transition phase. This report reviews our cases of HRPC. Materials and Methods: From January 2004, 50 HRPC cases were treated with dexamethasone (DEX). Of these, 31 cases were indicated for combination TAX che- motherapy (TAX + DEX). TAX was not approved for national insurance before August 2008, but because 24 of the 31 cases were shown to be DEX refractory, these 24 were allowed treatment with TAX. The remaining 7 of 31 received the combination treatment of TAX + DEX. The two groups of 24 and 7 cases were combined for analysis as those having re- ceived combination TAX chemotherapy. The remaining group of 19 cases received only DEX treatment. Results: Cases treated with TAX combina- tion therapy had a significantly longer sur- vival than those treated only with DEX (median 13.2 vs 11.2 months, hazard ratio 2.066, p=0.028). Even in DEX refractory cases, the TAX combination had a clinical significance with median overall survival of 13.1 months (hazard ratio 2.158, p=0.029). On univariate analysis perfor- mance status, PSA, alkaline phosphatase, and TAX therapy were significant factors. Of these, alkaline phosphatase and TAX therapy were also significant on multivari- ate analysis. Conclusions: TAX therapy is useful even in the DEX refractory status and should be indicated in less advanced disease. UP-2.123 Histology of Orchidectomy Specimens in Patients with Prostate Cancer Olapade-Olaopa E, Ukachukwu A, Oyelekan A, Shittu O, Okeke L Dept. of Surgery, University College Hos- pital, Ibadan, Nigeria Introduction and Objectives: The histol- ogy reports of bilateral orchidectomy specimens in prostate cancer patients were reviewed with the aim of identifying the incidence of testicular metastasis and the degree of testicular atrophy. Materials and Methods: 81 patients with histologically diagnosed prostate cancer had bilateral orchidectomy as their man- agement modality between 2001 and 2008. The orchidectomy specimens were studied by experienced pathologists and the reports stored in data banks. These were analysed retrospectively. Results: The mean age of the patients was 68.7 years (range 48 - 92 years). Only one specimen (1.2%) had evidence of tes- ticular metastasis while 53 (65.4%) showed evidence of testicular atrophy and 27 (32.2%) were reported as normal tes- tes. of the 53 specimens reported as atro- phic 15 (28.3%) showed mild atrophic changes and 38 (71.7%) showed moderate to severe atrophic changes. 5 of the 81 orchidectomy specimens (6.2%) had dif- ferent histology reports for the two testes. Conclusion: Bilateral orchidectomy speci- UNMODERATED POSTER SESSIONS UROLOGY 74 (Supplment 4A), October 2009 S269